NasdaqGM:CRVSBiotechs
Is It Too Late To Consider Corvus Pharmaceuticals (CRVS) After A 335% One Year Surge?
If you are wondering whether Corvus Pharmaceuticals stock still offers value after a big run, the next sections break down what the current price might imply about expectations.
The stock recently closed at US$14.59, with a 1 year return of 335.5% and a year to date return of 99.3%, alongside a 4.0% decline over the last 7 days and a 1.7% gain over the past 30 days.
Recent news coverage has focused on Corvus Pharmaceuticals within the context of its sector and ongoing product development...